全球首个DPP-1抑制剂获批;三部门联合发布《医疗广告认定指南》

氨基观察
Aug 13

氨基观察-消费医疗组原创出品作者 | 黄恺DPP-1抑制剂迎来历史性时刻。8月12日,Insmed宣布Brensocatib(商品名:Brinsupri)获FDA批准上市,用于治疗12岁及以上儿童和成人非囊性纤维化支气管扩张症患者。这标志着,全球首个DPP-1抑制剂获批上市,该疾病领域迎来首款靶向治疗药物。医疗广告需谨慎。8月13日,市场监管总局、国家卫生健康委、国家中医药局13日联合发布《...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10